Back to mobile site

More on INMB

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+41.7% Growth)
- Ratings (6.4 Score)

Upcoming Events

- Earnings (11/4/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

INmune Bio (NQ:INMB)
Delayed: 2.14 +0.09 (4.39%)
Prev. Close $2.05  
Open$2.07 
52 Wk High$ 
52 Wk Low$ 
Day High$2.19 
Day Low$2.06 
P/E N/A  
EPS$ 
Volume93,742 


Sep 16, 2026 08:05 PM Form 3 Inmune Bio, Inc. For: Sep 08 Filed by: SAPIRSTEIN JAMES
Sep 14, 2026 04:06 PM Form 8-K Inmune Bio, Inc. For: Sep 08
Sep 14, 2026 07:00 AM INmune Bio adds two executives to its board of directors
Sep 14, 2026 07:00 AM INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board
Sep 9, 2026 08:00 AM INmune Bio to Present at the H.C. Wainwright Global Investment Conference
Aug 26, 2026 07:02 AM INmune Bio files for EMA orphan drug status for its RDEB cell therapy
Aug 26, 2026 07:00 AM INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings
Aug 6, 2026 05:38 PM INmune Bio, Inc. (INMB) Tops Q2 EPS by 14c
Aug 6, 2026 04:10 PM Form 10-Q Inmune Bio, Inc. For: Jun 30
Aug 6, 2026 04:00 PM INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress
View All Articles

Entities mentioned with INMB

View All Entities